Pfizer investors stand with CEO Read even though he is 0 for 2 on megamergers

Eric Palmer

CEO Ian walked away from its $ 160 billion merger with Allergan this week after U.S. Treasury Department rule changes sucked the value out of its tax inversion benefits. But are not walking away from Read, this was the second time he was unable to pull off a major merger.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS